FrancophonIA/ELRC3.0 huggingface dataset:
English: SPRYCEL contains 0.25 mg benzoic acid in each mL of oral suspension and 0.25 mg sodium benzoate in each mL of oral suspension.
Danish: SPRYCEL indeholder 0,25 mg benzoesyre pr. ml oral suspension og 0,25 mg natriumbenzoat pr. ml oral suspension.
English: Among imatinib-intolerant patients, the estimated rate of PFS was 98% (95% CI: [95%-100%]) at 1 year and 94% (95% CI: [88%-99%]) at 2 years.
Danish: Blandt imatinib intolerante patienter var den estimerede hyppighed af PFS 98% (95% CI: [95%-100%]) efter et år og 94% (95% CI: [88%-99%]) efter to år.
English: This medicine has been prescribed for you.
Danish: Lægen har ordineret SPRYCEL til dig personligt.
English: Rates of MMR were consistently higher in dasatinib-treated patients compared with imatinib-treated patients.
Danish: Raten for MMR var konsekvent højere hos dasatinib behandlede patienter sammenlignet med imatinib behandlede patienter.
English: The rate of major molecular response (assessed in 19 patients with a CCyR) was 68% at 24 months.
Danish: Hyppigheden af major molekylært respons (vurderet hos 19 patienter med CCyR) ved 24 måneder var 68%.
English: Fluid retention Superficial oedema Pleural effusion Generalised oedema Congestive heart failure /cardiac dysfunctionb
Danish: Diarré Væskeretention Superficielt ødem Pleuraeffusion Generaliseret ødem Kongestivt hjertesvigt/hjerte-insufficiensb
English: During the consolidation blocks of chemotherapy, CBCs should be performed every 2 days until recovery (see sections 4.2 and 4.8).
Danish: Der skal tages CBC'er hver anden dag indtil restitution under konsolideringsserierne af kemoterapi (se pkt.
English: Minimum of 2 years follow up
Danish: Mindst 2 års opfølgning
English: The film-coated tablets must not be crushed, cut or chewed in order to maintain dosing consistency and minimise the risk of dermal exposure; they must be swallowed whole.
Danish: For at minimere risikoen for optagelse gennem huden og for at opretholde konsistens i doseringen må de filmovertrukne tabletter ikke knuses, deles eller tygges, men skal synkes hele.
English: Carton containing 30 x 1 film-coated tablets in perforated unit dose blisters.
Danish: Æske der indeholder 30×1 filmovertrukne tabletter i perforerede enkeltdosisblistere.
English: Cumulative rates of selected adverse reactions that were reported in the 100 mg once daily recommended starting dose are shown in Table 6a.
Danish: Den kumulative rate for udvalgte bivirkninger, som blev rapporteret ved den anbefalede startdosis på 100 mg én gang dagligt, er vist i Tabel 6a.
English: Not known hepatitis B reactivation
Danish: Ikke kendt reaktivering af hepatitis B Blod og lymfesystem
English: Notably, 22% of patients reported a complete cytogenetic response (CCyR) in the dasatinib arm while only 8% achieved a CCyR in the imatinib arm. With longer treatment and follow-up (median of 24 months), MCyR was achieved in 53% of the dasatinib-treated patients (CCyR in 44%) and 33% of the imatinib-treated patients (CCyR in 18%) prior to crossover.
Danish: Med længere behandling og opfølgning (middelværdi på 24 måneder) opnåedes MCyR hos 53% af de dasatinib behandlede patienter (CCyR hos 44%) og 33% af de imatinib behandlede patienter (CCyR hos 18%) inden crossover.
English: Not known fatal gastrointestinal haemorrhage* Hepatobiliary disorders
Danish: Ikke kendt letal gastrointestinal blødning*
English: Excipients: contains lactose monohydrate.
Danish: Hjælpestoffer: indeholder lactosemonohydrat.
English: In patients with Ph+ ALL treated with the 140 mg once daily regimen, the median duration of MaHR was 5 months the median PFS was 4 months, and the median overall survival was 7 months.
Danish: Hos patienter med Ph+ ALL, som blev behandlet med 140 mg én gang dagligt, var medianvarigheden af MaHR 5 måneder, median PFS var 4 måneder, og den samlede medianoverlevelse var 7 måneder.
English: Haematologic response rateb (%) MaHR (95% CI)
Danish: Hæmatologisk responsrateb (%) MaHR (95% CI)
English: Based on the Kaplan-Meier estimates, the proportion of patients who maintained MCyR for 1 year was 92% (95% CI: [85%-100%]) for dasatinib (CCyR 97%, 95% CI: [92%-100%]) and 74% (95% CI: [49%-100%]) for imatinib (CCyR 100%).
Danish: Baseret på Kaplan-Meier-estimater var andelen af patienter som opretholdt MCyR i et år 92% (95% CI: [85%-100%]) for dasatinib (CCyR 97%, 95% CI: [92%-100%]) og 74% (95% CI: [49%-100%]) for imatinib (CCyR 100%).
English: Heart and lungs: palpitations, irregular heartbeat, congestive heart failure, weak heart muscle, high blood pressure, increased blood pressure in the lungs, cough Digestive problems: appetite disturbances, taste disturbance, bloated or distended tummy (abdomen), inflammation of the colon, constipation, heartburn, mouth ulceration, weight increase, weight decrease, gastritis
Danish: Hjerte og lunger: hjertebanken, uregelmæssig hjerterytme (puls), hjertesvigt med ophobning af blod, svag hjertemuskel, højt blodtryk, forhøjet blodtryk i lungerne, hoste Fordøjelsesproblemer: appetitforstyrrelser, smagsforstyrrelser, opsvulmet eller oppustet mave (abdomen), betændelseslignende tilstand i tarmen, forstoppelse, halsbrand, sår i munden, vægtøgning, vægttab, irriteret maveslimhinde
English: powder for oral suspension (see Summary of Product Characteristics for SPRYCEL powder for oral suspension).
Danish: (se Produktresumé for SPRYCEL pulver til oral suspension).
English: Concomitant use of dasatinib and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing Hypericum perforatum, also known as St. John's Wort) may substantially reduce exposure to dasatinib, potentially increasing the risk of therapeutic failure.
Danish: Samtidig brug af dasatinib og lægemidler, der inducerer CYP3A4 (fx dexamethason, phenytoin, carbamazepin, rifampicin, phenobarbital eller naturlægemidler, der indeholder Hypericum perforatum, også kendt som perikon) kan i betydelig grad reducere eksponeringen af dasatinib og dermed øge risikoen for behandlingssvigt.
English: By 5 years 76%, p<.0022
Danish: Ved år 5 p<0,0022
English: Table 13: Long term efficacy of SPRYCEL in phase 3 dose optimisation study: imatinib resistant or intolerant chronic phase CML patientsa Minimum follow-up period
Danish: Tabel 13: Langvarig virkning af SPRYCEL i fase 3 dosisoptimeringsstudie: imatinib resistente eller intolerante patienter med CML i kronisk fasea Mindste opfølgningsperiode
English: Table 6a: Selected adverse reactions reported in a phase 3 dose optimisation study (imatinib intolerant or resistant chronic phase CML)a
Danish: Tabel 6a: Udvalgte bivirkninger, der blev indberettet i et fase 3-dosisoptimeringsstudie (imatinib intolerant eller resistent CML i kronisk fase)a
English: In patients with accelerated phase CML treated with the 140 mg once daily regimen, the median duration of MaHR and the median overall survival was not reached and the median PFS was 25 months.
Danish: Hos patienter med CML i accelereret fase, som blev behandlet med 140 mg én gang dagligt, blev medianvarigheden af MaHR og den samlede medianoverlevelse ikke nået; median PFS var 25 måneder.
English: An open-label, single-arm, multicentre study was conducted in patients with lymphoid blast phase CML or Ph+ ALL who were resistant or intolerant to prior imatinib therapy.
Danish: Der er gennemført et åbent, enkeltarms-, multicenter-studie med patienter med CML i lymfoid blastfase eller Ph+ ALL, som var resistente eller intolerante over for tidligere imatinibbehandling.
English: Efficacy results are reported in Table 11.
Danish: Effektresultaterne er angivet i Tabel 11.
English: What SPRYCEL contains The active substance is dasatinib.
Danish: SPRYCEL indeholder: Aktivt stof: Dasatinib.
English: A total of 109 patients received dasatinib 70 mg twice daily (99 resistant and 10 intolerant to imatinib).
Danish: I alt 109 patienter fik 70 mg dasatinib 2 gange dagligt (99 resistente og 10 intolerante over for imatinib).
English: Make sure bottle adapter is firmly pressed.
Danish: Det skal tilsikres, at adapteren er sat godt fast i flasken.
English: Common gastrointestinal bleeding*, colitis (including neutropaenic colitis), gastritis, mucosal inflammation (including mucositis/stomatitis), dyspepsia, abdominal distension, constipation, oral soft tissue disorder
Danish: Almindelig gastrointestinal blødning*, colitis (inklusive neutropenisk colitis), gastritis, inflammation i slimhinderne (inklusive mucositis/stomatitis), dyspepsi, abdominal distension, obstipation, forstyrrelser i bløddele i munden Ikke almindelig pankreatitis (inklusive akut pankreatitis), øvre gastrointestinalt ulcus, esophagitis, ascites*, analfissur, dysfagi, gastroøsofageal reflukssygdom
English: b Includes central nervous system haemorrhage, cerebral haematoma, cerebral haemorrhage, extradural haematoma, haemorrhage intracranial, haemorrhagic stroke, subarachnoid haemorrhage, subdural haematoma, and subdural haemorrhage.
Danish: b Inkluderer blødning i centralnervessystemet, cerebralt hæmatom, cerebral blødning, ekstradural hæmatom, intrakraniel blødning, hæmoragisk apopleksi, subaraknoidal blødning, subdural hæmatom og subdural blødning.
English: The median changes in QTcF from baseline were 3.0 msec in dasatinib-treated patients compared to 8.2 msec in imatinib-treated patients.
Danish: Medianændringerne i QTcF fra baseline var 3,0 msek.
English: Before you prepare a dose of SPRYCEL oral suspension for administration to the patient, get the following supplies ready:
Danish: Gør følgende hjælpemidler klar, før du klargør en dosis SPRYCEL oral suspension til administration til patienten:
English: Outer Carton: sprycel 70 mg
Danish: Ydre karton: sprycel 70 mg
English: The rate of major molecular response (all 25 treated patients with a CCyR) was 52% at 24 months.
Danish: Hyppigheden af major molekylært respons (alle 25 behandlede patienter med CCyR) ved 24 måneder var 52%.
English: Outer Carton: sprycel 140 mg
Danish: Ydre karton: sprycel 140 mg
English: 20 to less than 30 kg
Danish: 20 til mindre end 30 kg
English: In SPRYCEL-treated patients with newly diagnosed chronic phase CML who experienced grade 3 or 4 myelosuppression, recovery generally occurred following brief dose interruptions and/or reductions and permanent discontinuation of treatment occurred in 1.6% of patients after a minimum of 12 months follow-up.
Danish: Hos patienter med nyligt diagnosticeret CML i kronisk fase, som fik SPRYCEL, og som fik myelosuppression grad 3 eller 4, svandt dette som regel efter korte dosisafbrydelser og/ellerreduktioner.
English: The rate of major molecular response (all 22 treated patients with a CCyR) was 50% at 24 months.
Danish: Hyppigheden af major molekylært respons (alle 22 behandlede patienter med CCyR) ved 24 måneder var 50%.
English: The median time from diagnosis to start of treatment was 61 months.
Danish: Mediantiden fra diagnose til start af behandling var 61 måneder.
English: Number of patients (%) Transformation at 60 months, n/N (%) Rate of PFS at 60 months (95% CI) Rate of OS at 60 months (95% CI)
Danish: Antal patienter (%) Transformation efter 60 måneder, n/N
English: The mean Cmax and AUC of dasatinib adjusted for the 70 mg dose were decreased by 47% and 8%, respectively, in subjects with moderate hepatic impairment compared to subjects with normal hepatic function.
Danish: Hos forsøgspersoner med moderat leverinsufficiens var dasatinibs gennemsnitlige Cmax og AUC, justeret for 70 mg dosen, nedsat med henholdsvis 47% og 8% sammenlignet med forsøgspersoner med normal leverfunktion.
English: Each film-coated tablet contains 67.5 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 67,5 mg lactosemonohydrat.
English: Each film-coated tablet contains 189 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 189 mg lactosemonohydrat.
English: Stevens-Johnson syndromef Musculoskeletal and connective tissue disorders Very common musculoskeletal paing
Danish: Stevens-Johnsons syndromf Knogler, led, muskler og bindevæv
English: Each film-coated tablet contains 135.0 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 135,0 mg lactosemonohydrat.
English: Skin, hair, eye, general: skin tingling, itching, dry skin, acne, inflammation of the skin, persistent noise in ears, hair loss, excessive perspiration, visual disorder (including blurred vision and disturbed vision), dry eye, bruise, depression, insomnia, flushing, dizziness, contusion (bruising), anorexia, somnolence, generalised oedema Pain: pain in joints, muscular weakness, chest pain, pain around hands and feet, chills, stiffness in muscles and joints, muscle spasm
Danish: Hud, hår, øjne, generelt: prikken i huden, kløe, tør hud, akne, betændelseslignende tilstand i huden, vedvarende ringen for ørerne, hårtab, voldsom svedtendens, synsforstyrrelser (sløret syn og nedsat syn), tørre øjne, blå mærker, depression, søvnløshed, ansigtsrødme, svimmelhed, sår (blå mærker), appetitmangel, søvnighed, ophobning af vand i kroppen Smerter: ledsmerter, muskelsvaghed, brystsmerter, smerter i hænder og fødder, kulderystelser, stive muskler og led, muskeltrækninger
English: By 2 years 19%, p<.0008
Danish: Ved år 2 p<0,0008
English: In the Phase III dose-optimisation study in advanced phase CML and Ph+ALL, grade 3 or 4 elevations of transaminases or bilirubin were reported in 1% to 5% of patients across treatment groups.
Danish: I fase III-dosisoptimeringsstudiet i CML i fremskreden fase og Ph+ ALL, blev grad 3 og 4 forhøjelse af aminotransferaser eller bilirubin indberettet hos 1% til 5% af patienterne.
English: Table 1: Dosage of SPRYCEL tablets for paediatric patients with Ph+ CML-CP or Ph+ ALL Body weight (kg)a
Danish: Tabel 1: Dosering af SPRYCEL tabletter til patienter med Ph+ CML-CP eller Ph+ ALL.
English: e Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalised erythema, genital rash, heat rash, milia, miliaria, pustular psoriaisis, rash, rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, skin exfoliation, skin irritation, toxic skin eruption, urticaria vesiculosa, and vasculitic rash.
Danish: e Inkluderer lægemiddeludslæt, erytem, erythema multiforme, erythrosis, eksfoliativt udslæt, generaliseret erytem, genitalt udslæt, varmeudslæt, milia, miliaria, pustuløs psoriasis, udslæt, erytematøst udslæt, follikulært udslæt, generaliseret udslæt, makulært udslæt, makulopapuløst udslæt, papuløst udslæt, kløende udslæt, pustuløst udslæt, vesikulært udslæt, hudeksfoliation, hudirritation, toksisk huderuption, urticaria vesiculosa og vaskulitisk udslæt.
English: Holding the syringe tip firmly into the bottle, turn the bottle with the syringe upside down.
Danish: Mens sprøjtespidsen holdes godt på plads i flasken, vendes flasken om, så sprøjten har bunden i vejret.
English: Outer Carton: sprycel 20 mg
Danish: Ydre karton: sprycel 20 mg
English: 10 to less than 20 kg
Danish: 10 til mindre end 20 kg
English: In the Phase III dose-optimisation study in chronic phase CML, grade 3 or 4 elevations of transaminases or bilirubin were reported in ≤ 1% of patients with similar low incidence in the four treatment groups.
Danish: I fase III-studier vedrørende dosisoptimering ved CML i kronisk fase blev grad 3 og 4 forhøjelse i aminotransferaser eller bilirubin indberettet hos ≤ 1% af patienterne med ensartet lav forekomst i de 4 behandlingsgrupper.
English: Concomitant use of dasatinib and medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to dasatinib.
Danish: Samtidig brug af dasatinib og lægemidler eller stoffer, der er potente CYP3A4-hæmmere (fx ketoconazol, itraconazol, erythromycin, clarithromycin, ritonavir, telithromycin, grapefrugtjuice), kan øge eksponeringen for dasatinib.
English: Cardiac adverse reactions
Danish: Hjertebivirkninger
English: Figure 3: MR4.5 rates over time - all randomised patients in a phase 3 study of newly diagnosed patients with chronic phase CML
Danish: Figur 3: MR4.5-rater over tid - alle randomiserede patienter i et fase 3-studie med patienter med nyligt diagnosticeret CML i kronisk fase
English: The median time from diagnosis to start of treatment was 28 months.
Danish: Mediantiden fra diagnose til start af behandling var 28 måneder.
English: b Haematologic response criteria (all responses confirmed after 4 weeks): Complete haematologic response (CHR) (chronic CML): WBC ≤ institutional ULN, platelets <450,000/mm3, no blasts or promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <20%, and no extramedullary involvement.
Danish: b Hæmatologiske responskriterier (alle responser blev bekræftet efter 4 uger): Komplet hæmatologisk respons (CHR) (kronisk CML): WBC ≤ gældende ULN, trombocytter <450.000/mm3, ingen blastceller eller promyelocytter i perifert blod, <5% myelocytter plus metamyelocytter i perifert blod, basofile celler i perifert blod <20% og ingen ekstramedullær involvering.
English: In patients with myeloid blast phase CML treated with the 140 mg once daily regimen, the median duration of MaHR was 8 months, the median PFS was 4 months, and the median overall survival was 8 months.
Danish: Hos patienterne med CML i myeloid blastfase, som blev behandlet med 140 mg én gang dagligt, var medianvarighed af MaHR 8 måneder, median PFS var 4 måneder, og den samlede medianoverlevelse var 8 måneder.
English: The powder for oral suspension should be used for patients weighing less than 10 kg and patients who cannot swallow tablets.
Danish: SPRYCEL tabletter anbefales ikke til patienter, der vejer mindre end 10 kg. Pulveret til oral suspension bør bruges til patienter, der vejer mindre end 10 kg og patienter, der ikke er i stand til at synke tabletter.
English: Each film-coated tablet contains 27 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 27 mg lactosemonohydrat.
English: Improvements in haemodynamic and clinical parameters have been observed in patients with PAH following discontinuation of dasatinib.
Danish: Hos nogle patienter med PAH blev der observeret bedring af de hæmodynamiske og kliniske parametre efter ophør af dasatinib behandling.
English: Outer Carton: sprycel 100 mg
Danish: Ydre karton: sprycel 100 mg
English: Table 12: Efficacy of SPRYCEL in phase III dose-optimization study: imatinib resistant or intolerant chronic phase CML (2-year results)a
Danish: Tabel 12: Effekt af SPRYCEL i fase 3-studie vedrørende dosisoptimering: imatinib resistent eller -intolerant CML i kronisk fase (resultater ved år 2)a
English: Each film-coated tablet contains 94.5 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 94,5 mg lactosemonohydrat.
English: If you or your child could be allergic, ask your doctor for advice.
Danish: Kontakt lægen for råd, hvis du har mistanke om, at du eller dit barn er allergisk.
English: c Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (>0%-35%).
Danish: c Cytogenetiske responskriterier: fuldstændigt (0% Ph+ metafaser) eller delvist (> 0%-35%).
English: Outer Carton: sprycel 50 mg
Danish: Ydre karton: sprycel 50 mg
English: Each film-coated tablet contains 108 mg of lactose monohydrate.
Danish: Hver filmovertrukket tablet indeholder 108 mg lactosemonohydrat.
English: Diarrhoea Fluid retention Superficial oedema Pleural effusion Generalised oedema Pericardial effusion Pulmonary hypertension Haemorrhage Gastrointestinal bleeding a Phase 3 dose optimisation study results reported in recommended starting dose of 100 mg once daily (n=165) population
Danish: Gastrointestinal blødning a Resultater, som blev rapporteret i populationen med den anbefalede startdosis på 100 mg 1 gang dagligt (n=165) i fase IIIdosisoptimeringsstudiet
English: Based on the Kaplan-Meier estimates, the proportion of patients treated with dasatinib 100 mg once daily who maintained MCyR for 18 months was 93% (95% CI: [88%-98%]).
Danish: Baseret på Kaplan-Meier-estimater var antallet af patienter, som opretholdt MCyR i 18 måneder, 93% (95% CI: [88%-98%]) for de patienter, der blev behandlet med dasatinib 100 mg én gang dagligt.
English: The median time from diagnosis to start of treatment was 48 months.
Danish: Mediantiden fra diagnose til start af behandling var 48 måneder.
English: In patients with lymphoid blast phase CML treated with the 140 mg once daily regimen, the median duration of MaHR was 5 months, the median PFS was 5 months, and the median overall survival was 11 months.
Danish: Hos patienterne med CML i lymfoid blastfase, som blev behandlet med 140 mg én gang dagligt, var medianvarigheden af MaHR 5 måneder, median PFS var 5 måneder, og den samlede medianoverlevelse var 11 måneder.
English: Do not crush, cut or chew them.
Danish: Tabletterne må ikke knuses, deles eller tygges.
English: SPRYCEL 140 mg film-coated tablets
Danish: SPRYCEL 140 mg filmovertrukne tabletter
English: Heart and lungs: heart attack (including fatal outcome), inflammation of the lining (fibrous sack) surrounding the heart, irregular heartbeat, chest pain due to lack of blood supply to the heart (angina), low blood pressure, narrowing of airway that may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) of the lungs Digestive problems: inflammation of the pancreas, peptic ulcer, inflammation of the food pipe, swollen tummy (abdomen), tear in the skin of the anal canal, difficulty in swallowing, inflammation of the gallbladder, blockage of bile ducts, gastro-oesophageal reflux (a condition where acid and other stomach contents come back up into the throat) Skin, hair, eye, general: allergic reaction including tender, red lumps on the skin (erythema nodosum), anxiety, confusion, mood swings, lower sexual drive, fainting, tremor, inflammation of the eye which causes redness or pain, a skin disease characterized by tender, red, well-defined blotches with the sudden onset of fever and raised white blood cell count (neutrophilic dermatosis), loss of hearing, sensitivity to light, visual impairment, increased eye tearing, disturbance in skin colour, inflammation of fatty tissue under the skin, skin ulcer, blistering of the skin, nail disorder, hair disorder, hand-foot disorder, renal failure, urinary frequency, breast enlargement in men, menstrual disorder, general weakness and discomfort, low thyroid function, losing balance while walking, osteonecrosis (a disease of reduced blood flow to the bones, which can cause bone loss and bone death), arthritis, skin swelling anywhere in the body
Danish: Hud, hår, øjne, generelt: allergisk reaktion herunder ømme, røde knuder under huden (erythema nodosum), angst, forvirring, humørsvingninger, nedsat seksuallyst, besvimelse, rysten, øjenbetændelse som medfører røde øjne eller smerter i øjnene, en hudsygdom karakteriseret ved ømt, rødt, afgrænset udslæt med skjolder med pludselig feber og forhøjet antal hvide blodlegemer (neutrofil dermatose), høretab, øget lysfølsomhed, nedsat syn, tåreflåd, misfarvning af huden, betændelse i fedtvævet under huden, sår på huden, blæredannelse på huden, neglesygdom, hårsygdom, hånd-fod-syndrom, nyresvigt, hyppig vandladning, brystforstørrelse hos mænd, menstruationsforstyrrelser, generel svækkelse og utilpashed, nedsat funktion af skjoldbruskkirtlen, balancetab, mens man går, osteonekrose (en sygdom med nedsat blodtilførsel til knoglerne, som kan medføre knogletab og knogledød), leddegigt, hævelse af huden hvor som helst på kroppen
English: Figure 2: MMR rates over time - all randomised patients in a phase 3 study of newly diagnosed patients with chronic phase CML
Danish: Figur 2: MMR-rater over tid - alle randomiserede patienter i et fase 3-studie med patienter med nyligt diagnosticeret CML i kronisk fase
English: SPRYCEL 80 mg: the film-coated tablet is white to off-white, biconvex, triangular with “BMS 80” debossed on one side and “855” on the other side.
Danish: SPRYCEL 80 mg: Den filmovertrukne tablet er hvid til gråligt hvid, bikonveks, trekantet med “BMS 80” printet på den ene side og “855” på den anden.